BioPharm America 2011
Wednesday, 5:15–6:15 pm
Westin Boston Waterfront Hotel, Commonwealth A, Grand Ballroom Level
As the pace of technology accelerates exponentially, it pushes the limits on existing business models, regulations, and policy around personalized medicine, especially in the field of oncology. This session will explore the challenges around the introduction of next generation sequencing. On the side of industry, the lack of clear business models, and indeterminacy regarding clinical acceptance of next generation sequencing, leaves major stakeholders watching from the sidelines on where value is accreting. On the side of academia, major institutions and hospitals are becoming central aggregators of diverse clinical data sets supported by powerful bioinformatics and sequencing, making them attractive business collaborators for pharma. How will value be created for early stage algorithm-based diagnostics companies to attract investments? Will value continue to remain with therapeutics, while diagnostics are positioned as loss leaders? And in the end, on the side of partnering, will pharmaceutical companies place attenuated value on diagnostics as they partner with academia to build their PM franchises? Join this thought-provoking discussion as we consider how technological disruption around diagnostics will forge surprising business partnerships with, perhaps, unlikely partners.
Moderator:
Dan Rhodes – CEO, Compendia Bioscience
Panelists:
- Kevin Krenitsky – COO, Foundation Medicine
- Joseph Monforte – Executive VP and CSO, AltheaDx
- Robert J. Penny, MD, PhD – CEO, International Genomics Consortium; Founding CEO, Molecular Profiling Institute
- Dietrich A. Stephan – Founder and CEO, Institute for Individualized Health